CU20060121A7 - TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS - Google Patents

TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Info

Publication number
CU20060121A7
CU20060121A7 CU20060121A CU20060121A CU20060121A7 CU 20060121 A7 CU20060121 A7 CU 20060121A7 CU 20060121 A CU20060121 A CU 20060121A CU 20060121 A CU20060121 A CU 20060121A CU 20060121 A7 CU20060121 A7 CU 20060121A7
Authority
CU
Cuba
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
CU20060121A
Other languages
Spanish (es)
Other versions
CU23649B7 (en
Inventor
Petra Huber
Stefan Bracht
Dirk Schenk
Thomas Langguth
Michael Dittgen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Priority to CU20060121A priority Critical patent/CU23649B7/en
Publication of CU20060121A7 publication Critical patent/CU20060121A7/en
Publication of CU23649B7 publication Critical patent/CU23649B7/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles de plasma de al menos 1,0 ng / ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un período de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana.The invention relates to a patch comprising a drug layer with a low content of hormones, such as, for example, signodene, and optionally an estrogen (for example ethinyl estradiol). By applying the patch to a woman, plasma levels of at least 1.0 ng / ml of signodene are achieved under steady state conditions without the need to incorporate penetration enhancers or permeation enhancers in the drug-containing layer. Plasma levels of hormones that are achieved over a period of at least 1 week are also satisfactory, making the patch can be applied for use in female contraception with the concept of applying the patch once a week.

CU20060121A 2006-06-09 2006-06-09 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS CU23649B7 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20060121A CU23649B7 (en) 2006-06-09 2006-06-09 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060121A CU23649B7 (en) 2006-06-09 2006-06-09 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Publications (2)

Publication Number Publication Date
CU20060121A7 true CU20060121A7 (en) 2008-06-30
CU23649B7 CU23649B7 (en) 2011-04-26

Family

ID=44280800

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060121A CU23649B7 (en) 2006-06-09 2006-06-09 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Country Status (1)

Country Link
CU (1) CU23649B7 (en)

Also Published As

Publication number Publication date
CU23649B7 (en) 2011-04-26

Similar Documents

Publication Publication Date Title
CU20100143A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CY1115064T1 (en) HYDRAULIC INTERDERATIVE HYMN TRADE SYSTEM WITHOUT LEADING AID
MX2022008277A (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof.
ATE496617T1 (en) CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL USE OF NEUROTRANSMITTERS
SE0202857D0 (en) Method and compositions for preventing hormone induced adverse effects
DE602005026290D1 (en) COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS
MX2018011706A (en) Steroid hormone pharmaceutical composition.
WO2007035940A3 (en) Transdermal norelgestromin delivery system
CL2007002000A1 (en) Pharmaceutical preparation for oral administration with controlled release of active ingredient in the small intestine comprising inert carriers, active ingredients, an inner layer composed of 2 diffusion layers to control the release and a gastro-resistant layer; Preparation method.
WO2008116004A3 (en) Transdermal patch and method for delivery of vitamin b12
MY205229A (en) Oral dosage form with drug composition, barrier layer and drug layer
MX2020003044A (en) Dextromethorphan transdermal delivery device.
ATE382356T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND USE IN CANCER TREATMENT
UY37672A (en) VAGINAL RING FOR THE SIMULTANEOUS RELEASE OF TWO ACTIVE INGREDIENTS
PE20120956A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE
CU20060121A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
UY28668A1 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CR8059A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES
BR112014018426A8 (en) COMPOSITION AND DEVICE FOR TRANSDERMAL ADMINISTRATION, AND METHOD FOR ADMINISTERING A PROGESTIN
MX2015010967A (en) Transdermal formulations of laquinimod.
PE20070119A1 (en) NEW REGIMES FOR CONTROLLED DELIVERY DEVICES FOR CONTRACEPTION DRUGS
HN2010000081A (en) STRATRIENS 8-BETA-SUBSTITUTED AS SELECTIVE ACTION STROGENS
Kang et al. Tangeretin Ameliorates Podocyte Injury Through Blocking Epithelial to Mesenchymal Transition in High Glucose-exposed Podocytes and Diabetic Kidneys (P06-009-19)
TW200722092A (en) Low dose administration of a topical composition
WO2012031999A3 (en) Low-dose transdermal patches with high drug release

Legal Events

Date Code Title Description
FG Grant of patent